78
Participants
Start Date
May 20, 2018
Primary Completion Date
June 16, 2022
Study Completion Date
December 31, 2023
ChemoID assay
"The ChemoID test is a CLIA-certified and CAP-accredited drug response assay performed by a hospital clinical pathology laboratory that uses a patient's live tumor cells to indicate which chemotherapy agent (or combinations) will kill not only bulk of tumor cells, but importantly the cancer stem cells (CSCs) that are known to cause cancer to recur. During the assay, cancer stem cells and bulk tumor cells from an individual patient are exposed to FDA-approved chemotherapy drugs.~The test measures the cytotoxic effect of actual doses of standard-of-care chemotherapies. The ChemoID drug response assay reports a prioritized list of effective and ineffective chemotherapies. The test is designed to target cancer stem cells to mitigate tumor relapse."
Chemotherapy
Chemotherapies chosen by Physician or ChemoID assay are in the same list of FDA approved drugs to treat recurrent high-grade glioma
Allegheny Health Network, Pittsburgh
The Penn State Univeristy College of Medicine, Hershey
St. Luke's University Health Network, Bethlehem
Thomas Jefferson University Hospitals, Philadelphia
Charleston Area Medical Center, Charleston
University of Mississippi Medical Center, Jackson
Toledo University, Toledo
University of Cincinnati Cancer Institute, Cincinnati
Louisiana State University Health Sciences Center, New Orleans
Kaiser Permanente, Los Angeles
Keck School of Medicine of the University of Southern California, Los Angeles
Providence Cancer Center Oncology, Portland
Maine Medical Center Research Institute, Scarborough
Cordgenics, LLC
INDUSTRY